Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib

INTRODUCTION: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). This post hoc analysis assessed frequency or duration of early select non-serious adverse events (AEs; excluding infections), and their impact on treatment discon...

Descripción completa

Detalles Bibliográficos
Autores principales: Dikranian, Ara, Gold, David, Bessette, Louis, Nash, Peter, Azevedo, Valderilio F., Wang, Lisy, Woolcott, John, Shapiro, Andrea B., Szumski, Annette, Fleishaker, Dona, Wollenhaupt, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964869/
https://www.ncbi.nlm.nih.gov/pubmed/34921355
http://dx.doi.org/10.1007/s40744-021-00405-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964869/
https://www.ncbi.nlm.nih.gov/pubmed/34921355
http://dx.doi.org/10.1007/s40744-021-00405-w

Ejemplares similares